Researchers estimate that 123,000 to 193,000 U.S. adults were hospitalized each year with respiratory syncytial virus from the 2016-2017 RSV season through the 2022-2023 season, according to a new ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback